Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Global Med Technologies, Inc. (OTC: GLOB.OB) ("Global Med" or the "Company" ) arising from the recently-announced acquisition of the Company by Haemonetics Corporation ("Haemonetics" ). Under the terms of the merger agreement, Haemonetics will commence a tender offer in which the Company's stockholders will receive $1.22 in cash for each share of common stock owned, including converted common shares from the Company's Series A Convertible Preferred stock, implying a total value of approximately $60 million. This tender offer will remain open for only twenty (20) business days after its commencement, and may be followed by a short-form cash out merger without a shareholder vote.

The investigation is focused on the potential unfairness of the price to Global Med shareholders and the process by which the Company's Board of Directors considered and approved the transaction, particularly since the merger agreement includes a $2.6 million termination fee and a clause prohibiting the Board from discussing or seeking any superior proposals. Global Med has also granted Haemonetics a "top-up" option to bring Haemonetics' ownership of the Company's stock up to 90% if it owns at least 80% after the tender offer is complete.

If you are interested in discussing your rights as a Global Med shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, D.C. offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it .